Immunis, Inc., a private biotechnology company developing a novel treatment for age and disease-related immune decline, is thrilled to appoint Mark Cabato as Chief Business Officer. Mark has more than 20 years of healthcare finance experience having spent the last 15 years at a large global financial institution where he was recently a director in the healthcare corporate and investment banking unit. He was responsible for large global pharmaceutical sector coverage and provided both financial solutions and strategic advice.
His versatility and collaborative mind-set will be important in forging new strategic growth opportunities and are a welcomed and valuable addition to the Immunis team.
“I am truly grateful and excited to join this talented and passionate scientific team at Immunis dedicated to addressing the unmet needs of an increasingly aging society,” says Mark. “I look forward to transitioning to an industry role where I can leverage my experience to drive the growth and business development of the secretome platform.”
About Immunis Inc.
Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The investigational product line leverages Immunis’ leading-edge capabilities in secretome technology to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations. For additional information about Immunis’ Phase 1/2a clinical trial please visit: www.immunisbiomedical.com
Cautionary Note Regarding Forward-Looking Statements
This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.